| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Product and service revenue, net | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
License revenue | |||||||||
- | - | - | - | - | - | 50 | 50 | 18 | - |
Total revenue | |||||||||
- | - | - | - | - | - | 50 | - | - | - |
Operating expenses | |||||||||
Research and development | |||||||||
- | - | 10,097 | 10,402 | 14,967 | 22,376 | 16,550 | 6,044 | - | - |
Research and development | |||||||||
12,622 | 6,829 | - | - | - | - | - | - | 6,648 | 1,972 |
Research and development - related party (Note 9) | |||||||||
- | - | 323 | 143 | 143 | 113 | 45 | - | - | - |
General and administrative | |||||||||
5,954 | 4,355 | 5,255 | 6,536 | 9,055 | 8,957 | - | 5,826 | 4,504 | 4,732 |
Selling, general and administrative | |||||||||
- | - | - | - | - | - | 7,477 | - | - | - |
Total operating expenses | |||||||||
18,576 | 11,184 | 15,676 | 17,082 | 24,167 | 31,448 | 24,073 | 11,870 | 11,152 | 6,704 |
Loss from operations | |||||||||
- | - | - | - | - | - | -24,023 | - | - | - |
Other income (expense) | |||||||||
Interest income (expense) | |||||||||
77 | -5 | - | - | - | - | - | - | - | - |
Interest (expense) income | |||||||||
- | - | 3 | 23 | 11 | 22 | - | - | - | - |
Related party interest income (Note 10) | |||||||||
- | - | - | 0 | 48 | 120 | - | - | - | - |
Interest (expense) income | |||||||||
- | - | - | - | - | - | 12 | - | - | - |
Interest expense | |||||||||
- | - | - | - | - | - | - | - | 8 | 19 |
Unrealized loss on fair value of debt instruments | |||||||||
- | - | - | - | - | - | - | - | -5,585 | 37 |
Derivative gain | |||||||||
4,869 | 45,298 | -36,218 | -915 | 0 | 0 | -516 | 205 | -1,555 | -1,367 |
Loss from disposal of fixed assets | |||||||||
0 | -123 | 0 | - | - | - | - | - | - | - |
Total other income (expense) | |||||||||
- | - | -36,215 | - | - | - | - | - | - | - |
Unrealized loss on trading security | |||||||||
- | - | - | -146 | 0 | 0 | - | - | - | - |
Interest income | |||||||||
- | - | - | - | - | - | - | 21 | 6 | 0 |
Loss from equity investment in Aytu BioScience, Inc. | |||||||||
- | - | - | -1,043 | 0 | 0 | - | - | - | - |
Total other income (expense) | |||||||||
4,946 | 45,170 | - | -2,081 | 59 | 142 | -504 | 227 | -7,142 | -1,348 |
Net loss from continuing operations | |||||||||
- | - | - | -19,163 | -24,107 | -31,305 | - | - | - | - |
Loss from discontinued operations (Note 4) | |||||||||
- | - | - | 0 | -9,606 | -7,743 | - | - | - | - |
Total net loss | |||||||||
- | - | - | -19,163 | -33,713 | -39,048 | -24,528 | -11,593 | -18,359 | - |
Net loss applicable to non-controlling interest | |||||||||
- | - | - | 0 | -1,703 | -923 | -519 | - | - | - |
Net loss, before income tax | |||||||||
- | - | - | - | - | - | - | - | -18,276 | -8,053 |
Foreign tax expense | |||||||||
- | - | - | - | - | - | - | - | 82 | - |
Net (loss) income | |||||||||
-13,630 | 33,986 | -51,891 | -19,163 | -32,010 | -38,125 | -24,008 | -11,593 | -18,359 | -8,053 |
Net (loss) income per common share: Basic | |||||||||
-0.10 | 0.46 | - | - | - | - | - | - | - | - |
Net (loss) income per common share: Diluted | |||||||||
-0.14 | -0.12 | - | - | - | - | - | - | - | - |
Basic weighted-average common share outstanding | |||||||||
130,601 | 73,358 | - | - | - | - | - | - | - | - |
Weighted average number of common shares outstanding: Diluted | |||||||||
131,135 | 91,091 | - | - | - | - | - | - | - | - |
From continuing operations | |||||||||
- | - | - | -0.36 | -0.46 | -0.62 | - | - | - | - |
From discontinuing operations and non-controlling interest | |||||||||
- | - | - | 0.00 | -0.16 | -0.14 | - | - | - | - |
Basic and diluted net (loss) income per common share | |||||||||
- | - | -0.79 | -0.36 | -0.62 | -0.76 | -0.63 | -0.34 | -0.71 | -0.49 |
Weighted average number of common shares outstanding | |||||||||
- | - | 65,297 | 53,773 | 51,992 | 50,226 | 38,294 | 33,983 | 26,013 | 16,288 |